2025 made one thing clearer: AI in IVF is moving beyond “promising tools” toward practical questions: where it fits in the workflow, what blocks adoption, and what builds trust. A useful snapshot comes from a global survey of fertility specialists comparing perspectives across 2022 and 2025.

(Journal of IVF-Worldwide, 2025)

1) Embryo selection remains the core use case

Across the surveys, embryo selection continues to be the most common place clinicians think about applying AI because it sits at a high-impact decision point and is historically subject to human variability.

2) Adoption intent is strong, but barriers are practical

Interest is growing, but adoption is often constrained by cost, lack of training, and uncertainty around validation and governance, not just model performance. In other words, the bottleneck is increasingly about implementation and workflow readiness.

3) Trust is the new battleground: explainability + human oversight

As AI tools enter routine decision-making, the focus shifts to trust: why a recommendation is made, how it should be used, and how humans stay in control. This is echoed across recent reviews emphasizing responsible deployment, fairness, and clinical generalizability.

(Journal of Gynecology Obstetrics and Human Reproduction, 2025) (Reproductive BioMedicine Online, 2025)

These trends point to one direction: AI that fits real workflows and strengthens consistency. Kai Health will continue evolving Vita Embryo accordingly, and stay closer to clinics with practical support and evidence-led messaging in 2026.